Abbott (NYSE: ABT) and BG Medicine, Inc. announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott’s ARCHITECT immunochemistry instrument platform, specifically the company’s i1000SR and i2000SR instruments. The agreement grants Abbott a [...]

Abbott (NYSE: ABT) announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new, compact hematology instrument, CELL-DYN Emerald(TM). Abbott’s CELL-DYN Emerald will expand the company’s hematology platform by offering a high performance, affordable solution for small to mid- sized clinical laboratories.